| Literature DB >> 32452714 |
Chul S Ha1, Michael LeBlanc2, Heiko Schöder3, Chelsea C Pinnix4, Nancy L Bartlett5, Andrew M Evens6, Eric D Hsi7, Lisa Rimsza8, Michael V Knopp9, Jun Zhang9, John P Leonard10, Brad S Kahl5, Hongli Li2, Sonali Smith11, Louis S Constine12, Jonathan W Friedberg13.
Abstract
The role of radiotherapy (RT) in the management of advanced Hodgkin Lymphoma (HL) is inadequately defined in this era of functional imaging with PET scan. SWOG-S0816 treated advanced stage Hodgkin lymphoma patients with ABVD+/- escBEACOPP and no RT. We queried whether RT might have benefited patients in S0816 who would have met the GHSG-HD15 criteria for RT by simulating RT use as per HD15 criteria of PET + residual disease ≥2.5 cm. Receiver-operating-characteristics analyses were performed by varying disease-control rates within radiation fields and size cutoffs for residual disease. Among the 49 PET3+ S0816 patients, RT would have raised the 2-year PFS from 30.6% to 50.2-58.1% using three residual disease cutoffs (1.5, 2.0 and 2.5 cm) and assuming 80 and 90% in-field control rates . Although there may be improvement in PFS as size cutoff point is lowered, consequential toxicities from RT require further definition to assess relative benefits.Entities:
Keywords: Hodgkin lymphoma; PET (positron emission tomography); radiotherapy
Mesh：
Substances：
Year: 2020 PMID： 32452714 PMCID： PMC7704391 DOI： 10.1080/10428194.2020.1768388
Source DB: PubMed Journal: Leuk Lymphoma ISSN： 1026-8022